CWBR Stock Overview
A clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CohBar, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.41 |
| 52 Week High | US$1.01 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -21.98% |
| 3 Month Change | -16.33% |
| 1 Year Change | -49.69% |
| 3 Year Change | -96.26% |
| 5 Year Change | -99.41% |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
CohBar stock gains on 1-for-30 reverse stock split
Sep 22Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation
Jun 13
CohBar appoints Joseph Sarret as CEO and Director
Apr 27CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS
Jan 11CohBar EPS in-line
Nov 16CohBar (CWBR) Investor Presentation - Slideshow
Oct 31Shareholder Returns
| CWBR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -0.5% |
| 1Y | -49.7% | -6.4% | 23.2% |
Return vs Industry: CWBR underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: CWBR underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| CWBR volatility | |
|---|---|
| CWBR Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CWBR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CWBR's weekly volatility has decreased from 8600244% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | n/a | www.cohbar.com |
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
CohBar, Inc. Fundamentals Summary
| CWBR fundamental statistics | |
|---|---|
| Market cap | US$1.19m |
| Earnings (TTM) | -US$12.69m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CWBR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CWBR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.69m |
| Earnings | -US$12.69m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CWBR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 06:34 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CohBar, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Kumaraguru Raja | Brookline Capital Markets |
| Michael Morabito | Chardan Capital Markets, LLC |